Trxade Group (OTCMKTS:TRXD) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday.
According to Zacks, “Trxade Group, Inc. is a web based market platform that enables trade among healthcare buyers and sellers of pharmaceuticals, accessories and services. The company’s products and services include Web-based pharmaceutical marketplaces comprising Trxade.com and Trxade.com; Pharmabayonline, which offers access to proprietary pharmaceutical data analytics to the United States-based independent pharmacies; RxGuru, a software as a service-based desktop application that provides daily drug pricing and analytics to the independent pharmacists; and Pinnacle Tek, an information technology consulting and staffing solution. Trxade Group, Inc. is based in Lutz, Florida. “
A number of other brokerages have also commented on TRXD. Taglich Brothers reissued a “speculative buy” rating on shares of Trxade Group in a research report on Friday, October 6th. ValuEngine raised shares of Trxade Group from a “sell” rating to a “hold” rating in a research report on Thursday.
Trxade Group Company Profile
Trxade Group, Inc (Trxade) designs, develops, owns and operates a business-to-business Web-based marketplace focused on the United States pharmaceutical industry. The Company’s products and services include Trxade.com, InventoryRx.com, Pharmabayonline and RxGuru. Its services are distributed through its online platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trxade Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trxade Group and related companies with MarketBeat.com's FREE daily email newsletter.